Search Videos and More
ASCO 2025: GU Highlights
In the following videos, Faculty from Dana-Farber Cancer Institute review GU Oncology highlights from the 2025 ASCO Annual Meeting, held in Chicago, May 30 - June 3, 2025.Disparities Research Symposium Focuses on Clinical Trials
Above all else, clinical research is about action – moving promising findings from the lab to patient care. The same can now be said about addressing disparities in clinical trial participation: that such disparities exist is well documented; the question going forward is how to reduce them.Treatment Guideline: Adjuvant Abemaciclib for Early-Stage, Hormone-Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Cancer Institute held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant abemaciclib in patients with early-stage, hormone-receptor-positive breast cancer.Treatment Guideline: Adjuvant Ribociclib for Early-Stage Hormone Receptor-Positive Breast Cancer - Updated in 2025
The Breast Oncology Center at Dana-Farber Cancer Institute held multidisciplinary meetings to discuss recommendations regarding the use of adjuvant ribociclib in patients with early-stage hormone receptor-positive breast cancer.Treatment Guideline: Patients With a History of Breast Cancer who Desire Pregnancy
The Breast Oncology Center at Dana-Farber Cancer Institute held multidisciplinary meetings to discuss recommendations for patients with a history of breast cancer who desire pregnancy.New Guidelines for Radiation Therapy for HPV-associated Head and Neck Cancer
Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: An ASTRO clinical practice guidelineAnti-inflammatory Drug Celecoxib Could Reduce Risk of Colon Cancer Recurrence for a Subset of Patients
Review analysis of data from a randomized clinical trial for patients with stage 3 colon cancerKimia Sorouri, MD, MPH Discusses Fertility and Breast Cancer
Study shows most women attempting to conceive after breast cancer treatment can do so and give birth. Dana-Farber's Kimia Sorouri, MD, MPH, discusses the first prospective study with more than 10 years of follow-up that also accounts for conception attempts.Toni Choueiri, MD Provides Kidney Cancer CLEAR Trial biomarker analysis
Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.Toni Choueiri, MD Discusses Kidney Cancer JAVELIN 101
Kidney cancer research at ASCO24: Final analysis in JAVELIN Renal 101 trial confirms the efficacy and manageable safety profile of avelumab plus axitinib versus sunitinib in patients with advanced kidney cancer. Dana-Farber's Toni Choueiri, MD, explains more.Andrew Hantel, MD Reviews Cancer Care and Greenhouse Gases
Telehealth can significantly reduce greenhouse gas emissions from cancer care, with research showing decentralized cancer care and telemedicine can cut emissions 33% compared to traditional in-person visits.Richard Leiter, MD, MA Featured in ASCO Voices
Palliative care physician Richard Leiter, MD, MA, recounts his support of a young patient with end-of-life care and the complexities of communicating with his family.